Biopharma news, November 16, 2026
4 stories
In this digest: Approval 4
Top stories
Gazyva Wins Kidney Disease Approval
The FDA approved Roche's Gazyva for adults with primary membranous nephropathy at risk of progression, making it the first FDA-approved treatment for the disease. In the phase 3 MAJESTY trial, complete remission of proteinuria at two years occurred in 36.1% of patients receiving Gazyva versus 5.7% receiving tacrolimus. Roche reported no new safety signals and said regulators are also considering Gazyva for systemic lupus erythematosus.
Source types: Press release · News article
FDA Approves Perioperative Imfinzi Regimen
The FDA approved neoadjuvant Imfinzi plus enfortumab vedotin-ejfv followed by adjuvant Imfinzi for adults with muscle-invasive bladder cancer who are ineligible for or refuse cisplatin-based chemotherapy.
Read more about FDA Approves Perioperative Imfinzi Regimen
In the phase III VOLGA trial, the regimen reduced the risk of an event by 49% and the risk of death by 42% versus cystectomy with or without approved adjuvant treatment. Grade 3 or 4 adverse events occurred in 64% of patients receiving the regimen versus 44% in the comparator arm; applications are also under review in the EU, Japan and other countries.
- Drugdurvalumab
- Drugenfortumab vedotin
- TargetProgrammed cell death protein 1 ligand 1
- TargetNectin cell adhesion molecule 4
Source types: Press release
FDA Approves Imfinzi ADC Regimen
The FDA approved neoadjuvant Imfinzi plus enfortumab vedotin followed by adjuvant Imfinzi after radical cystectomy for eligible adults with muscle-invasive bladder cancer.
Read more about FDA Approves Imfinzi ADC Regimen
The regimen is intended for patients who are ineligible for or decline cisplatin-based chemotherapy, and the approval came six weeks ahead of the FDA's target review date. The approval was based on the phase 3 VOLGA trial, which enrolled 695 patients; its results were presented at ESMO 2026 and published in the New England Journal of Medicine.
Source types: News article
News in brief
China Approves Hengrui ANGPTL3 Antibody
Read more about China Approves Hengrui ANGPTL3 Antibody
China approved Hengrui's ANGPTL3 antibody 艾轻达 for use alongside a low-fat diet and other lipid-lowering drugs in adults and adolescents aged 12 or older with homozygous familial hypercholesterolemia. In the phase 3 SHR-1918-301 trial, the treatment reduced LDL cholesterol by 64.2% relative to placebo at week 12; 88.9% of treated patients achieved at least a 50% reduction from baseline at week 24. The drug is administered as a 600 mg subcutaneous injection every four weeks. Additional indications remain in clinical development.
Source types: Press release
Sources are available to Gosset users. Log in to see them.
All digests
- November 15, 2026 4 stories
- November 14, 2026 5 stories
- November 13, 2026 5 stories
- November 12, 2026 10 stories
- November 11, 2026 10 stories
- November 10, 2026 10 stories
- November 9, 2026 10 stories
- November 8, 2026 9 stories
- November 7, 2026 7 stories
- November 6, 2026 10 stories
- November 5, 2026 10 stories